Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of sintilimab plus first-line chemotherapy for relapsed or metastatic head and neck squamous cell carcinoma
ChiCTR2300070498Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in head and neck squamous cell carcinoma (HNSCC), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Objective response rate. Started Apr 2023; status: recruiting.
02
Drugs
sintilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2300070498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070498.